NCT05571787 - HMPL-523 Food Effect and Proton Pump Inhibitor Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

September 22, 2022

Study Completion Date

September 22, 2022

Conditions

Relapsed or Refractory Lymphoma

Interventions

DRUG

HMPL-523

700 mg HMPL-523 will be administered by mouth once daily on Day 1, Day 8, Day 15, and Day 26

DRUG

Rabeprazole

40 mg of rabeprazole will be administered by mouth once daily in the morning from Day 20 to Day 26

Trial Locations (1)

PPD Austin, Austin